The INNOTEST® hTAU Ag is a solid-phase enzyme immunoassay for the quantitative determination of Tau protein in human cerebrospinal fluid (CSF). This assay measures the biomarker called total Tau, including the six isoforms (352 to 441 amino acids) from the brain.
The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression (1-6).
Art. no. 81572 (96T- CE) - see also Art. no. 81583 (96T - RUO) - Please contact your local Fujirebio representative for the availability of this product in your country.
Features & Benefits
- User-friendly enzyme immunoassay, standard technology
- Generic and color-coded components
- Easily automated on microplate processor (generic components)
- Ready-to-use Calibrators reduce inter and intra run variation
- Run Validation Controls for assay run validation
- Small sample volume: 25 µL CSF. Duplicate testing is strongly recommended and requires 2 x 25 µL CSF.
- Limit of Detection: 34 pg/mL
Calibrator range: 50 to 2500 pg/mL
- This assay should be used in combination with the Tau Ag CAL-RVC pack, article no. 81573.
- Andreasen et al. Evaluation of CSF-tau and CSF- Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch Neurol 2001;58:373-379.
- Sunderland et al. Decreased b-amyloid1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer disease. Journal of the American Medical Association 2003;289:2094-2103.
- Hansson et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234.
- Mattsson et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302(4): 385-393.
- Tabaraud et al. Alzheimer CSF biomarkers in routine clinical setting. Acta Neurol Scand. 2012; 125(6): 416-23.
- Buchhave et al. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69(1): 98-106.
Additional useful information about Alzheimer’s disease can be found on the following websites:
The Alzheimer forum site:
These resources are either available in free access or for users holding a Premium eServices account: